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Preface
The EMCDDA has been monitoring infections in injecting drug users since 1996 through its  
‘Drug-related infectious diseases’ project (DRID). This project is one of the five ‘key 
epidemiological indicators’ used by the EMCDDA and its partners in the Reitox network to monitor 
drug use and health consequences in Europe. Data are collected annually on the prevalence of 
HIV and viral hepatitis (hepatitis B and C) in samples of IDUs tested routinely in drug or health 
services or recruited in sero-epidemiological studies.
Since about 2006, attention in the DRID project has shifted from setting up the Europe-wide 
collection and analysis of available prevalence data to giving more attention to improving 
comparability of the primary data collection systems, resulting in a draft DRID protocol which is 
currently being finalised. One of the new aspects in the DRID data collection is the development 
of behavioural data monitoring, including the collection of HIV and hepatitis C testing uptake, as 
important indicators of service access in IDUs.
Data from different studies including those presented in the annual DRID expert meetings 
indicated that testing uptake of HIV, viral hepatitis and other infections among IDUs are low in 
many European countries. IDUs are still often a relatively ‘hidden’ population that is not easily in 
contact with health services and where various infectious diseases may go unnoticed for many 
years. In this group, with often frequent risk behaviours, it is crucial that those infected are aware 
of their infection in order that they can avoid passing the infection to others and can be referred to 
appropriate treatment. 
Therefore, EMCDDA and DRID experts recognised a need for guidance on providing IDUs 
with a medical examination and testing for HIV, viral hepatitis and several other infections on a 
regular basis. In addition, improving testing uptake in this group would benefit epidemiological 
surveillance and monitoring as carried out at the national and international level. 
These operational guidelines are accompanied by a recommended package of prevention and 
primary care in relation to injecting drug users and infections. Treatment and other specialist care 
are not discussed in detail but are dealt with by indicating referral to appropriate services.
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Infectious diseases are among the most serious health consequences of injecting drug use and can 
lead to significant healthcare costs. Injecting drug users are vulnerable to a range of infectious 
and communicable diseases through a variety of risk behaviours, and because of underlying 
conditions such as poor hygiene, homelessness and poverty. This leads to higher morbidity and 
mortality in this group as compared with the same age groups in the general population. In 
addition, IDUs can act as a core group carrying infections that may pose a risk to the general 
population.
Although HIV and hepatitis C infections remain the most important public health problem among 
IDUs, this document recognises that other blood-borne viral infections and various bacterial 
infections also play an important role in the health and well-being of IDUs. As the coverage of 
effective antiretroviral treatment and treatment for other infections in IDUs is being scaled up, 
access to and uptake of testing for HIV and other infectious diseases in IDUs also needs to be 
increased.
Evidence-based interventions such as opioid substitution treatment, needle exchange programmes 
and other elements of the ‘comprehensive package’ for IDUs are important measures to prevent 
HIV infection, hepatitis and other infections in this group (WHO, UNODC and UNAIDS 2009), 
given that prevention of injecting drug use itself still proves to be very difficult.
The recommendations in this document are primarily targeted at high-income countries with low-
level or concentrated HIV epidemics where recorded infections are largely confined to individuals 
with risk behaviour, such as IDUs. This includes most European countries.
The objectives
The objectives of provider-initiated examination, testing and counselling of IDUs are to:
improve the general health of the individual IDU; ▯
improve the uptake of testing for HIV and other drug-related infections; ▯
increase IDUs’ access to treatment for HIV and other infectious diseases; ▯
improve the diagnosis of chronic infections that need specialist care; ▯
increase vaccination coverage among IDUs; ▯
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encourage IDUs to be more actively engaged in their own healthcare; ▯
improve IDUs’ access to prevention counselling and information; ▯
improve surveillance of HIV infection, hepatitis and other infections in IDUs. ▯
The consultation
These guidelines recommend that health providers should initiate examination, testing and 
counselling in IDUs in different health settings including primary healthcare, special health services 
for IDUs, low threshold service centres visited by IDUs, rehabilitation centres, dedicated sexually 
transmitted infections (STI) clinics and prison healthcare facilities. The consultation should include:
medical history and physical examination; ▯
pre-test counselling, informed consent and possibility to decline tests; ▯
testing for infections; ▯
post-test counselling; ▯
prevention counselling; ▯
vaccination; ▯
follow-up and referral routines; ▯
frequency of examination and testing; ▯
ethical considerations. ▯
Testing for infections
This guidance document recommends a provider-initiated, voluntary and confidential approach 
to testing and counselling. Provider-initiated means that examination, testing and counselling is 
recommended by a healthcare provider to people attending facilities as a standard component 
of medical care. Voluntary means that although testing is a standard part of the medical care, 
the individual is informed about the tests and their potential consequences and gives (informed) 
consent to taking them.
An individual should always be able to decline testing for one or more infections after receiving 
pre-test information without fear of coercion or negative consequences. This approach stresses 
14
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that no tests should be done against a person’s wishes or without their knowledge, that 
informed consent must be given and that test results will remain confidential. In situations where 
these conditions are likely not to be met (for instance in closed settings such as prisons) it is 
recommended that provider-initiated testing is not implemented, and instead voluntary counselling 
and testing are made available at the individual’s request.
In provider-initiated testing the following tests are recommended as a standard offer to all IDUs:
serology testing for HIV, hepatitis B, hepatitis C, hepatitis D (if there is evidence of chronic or  ▯
recent hepatitis B) hepatitis A, and syphilis;
swab for culture from abscesses and skin lesions; ▯
tests for biochemical analysis — alanine aminotransferase (ALAT, liver function test), aspartate  ▯
aminotransferase (ASAT, liver function test), bilirubin;
other general blood tests — erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP),  ▯
haemoglobin and white blood cell count;
tests for tuberculosis. ▯
The frequency with which a client should be re-examined and re-tested depends on the individual 
risk of exposure to infectious agents. For individuals with ongoing injecting drug use this risk is 
usually very high and frequent re-examination and re-testing are recommended. It is important 
to reduce the period of undiagnosed carrier state following infection and thus reduce the risk 
of infections being transmitted to others. For practical reasons, and taking into account the 
mentioned considerations, it is recommended that examination and testing are offered to IDUs at 
least once every 6 to 12 months.
While this document supports a strategy of increased testing of HIV and other infections among 
IDUs in healthcare settings, it does not support a policy of testing without informed consent, 
without pre- and post-testing counselling or where the confidentiality of test results cannot be 
guaranteed. It should be stressed that no tests should be done against a person’s wishes and 
without their knowledge, and adequate information should always be provided to enable the 
individual to make an informed decision about whether or not to take each test being offered.
The conditions under which IDUs undergo testing for HIV and other infections must be anchored 
in a human rights approach, where the client is an equal partner in the process, and must respect 
the ethical principles detailed in this document, such as guaranteed confidentiality of test results. 
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Healthcare providers must follow equally high standards as for other patient groups with regard 
to confidentiality and unauthorised disclosure of test results. It must be made explicit that when an 
individual declines to be tested, or in cases where test results are positive, this will not affect an 
individual’s access to other services, such as drug dependence treatment. The healthcare provider 
takes the final responsibility for ensuring that adequate procedures and conditions exist before a 
test is taken.
Policymakers should implement or safeguard and monitor adequate conditions for testing 
vulnerable populations such as IDUs at local and national levels. However, this is beyond the 
scope of these guidelines and for these aspects we refer to specific HIV testing guidance being 
developed by UNODC, WHO and UNAIDS (see Part 2 of these guidelines).
16
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Methodology and scope
This document is a result of discussions at the annual EU expert meetings on drug-related 
infectious diseases (DRID) held by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). While the main objective of the work on drug-related infectious diseases at the 
EMCDDA is to develop indicators for more reliable and comparable monitoring of hepatitis B/C 
and HIV in injecting drug users, a need was identified for methods and guidance to be developed 
to improve the quality of testing and counselling processes among IDUs and to increase testing 
uptake for HIV and other drug-related infections.
The development of these guidelines has been based on an ongoing review of materials such as 
research reports, position statements, policy documents, journal articles and clinical guidelines. 
Recommendations given here are generally based on good clinical practice as well as information 
from epidemiological and other studies among IDUs. The scope of these guidelines, however, 
is not to document the benefits of tests, counselling and preventive measures in evidence-based 
terms, nor to provide a thoroughly documented literature review of the health risks associated with 
injecting drug use, but rather to present a short and readable document that is directly useful for 
the primary healthcare provider who is in contact with IDUs regarding the decisions to test for 
infectious diseases. In addition, although increased testing among IDUs is essential for improving 
the access to treatment and specialised follow-up care of IDUs with an infectious disease(s), the 
description of specific treatments of various infections is not within the scope of these guidelines.
Between July and December 2008, participants of the 2008 DRID expert meeting and other 
members of the EMCDDA DRID expert network were invited to comment on a consolidated draft 
version of these guidelines, which was also made available on the Internet. The document was 
subsequently revised to take into account all the comments that were received.
IDUs are a well-defined population and they are at very high risk of contracting infectious 
diseases. For the purpose of these guidelines, an IDU is defined as any person who has ever in 
his/her life injected a substance for non-medical purposes at least once. IDUs who continue to 
inject are at very high risk of contracting a new infection and are likely to benefit from frequent 
repeat testing. These guidelines are primarily aimed at active IDUs (those who have injected 
at least once since their last test), and IDUs who have stopped injecting. However, healthcare 
providers may apply the same procedures to other (‘never-injecting’) drug users who are at risk 
of infection — for example through involvement in sex work or other high-risk sex, through other 
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drug-related infection risks such as sharing straws to snort cocaine, through tattooing, etc. The 
guidelines may also be applied to other vulnerable populations than drug users who are at risk of 
infections (e.g. prisoners), although the healthcare provider should check whether specific issues 
need to be taken into account that are not covered in these guidelines. In particular, prisoners and 
people in other closed settings may be specifically vulnerable to non-voluntary testing, breaches 
in confidentiality, discrimination, etc. and in these circumstances extra care should be taken 
to ensure that testing occurs under satisfactory conditions. These are described in more detail 
elsewhere (Jürgens, 2008).
While this document may be useful for a wider audience, it is mainly intended as a practical 
tool for healthcare providers in the public and private sectors who provide primary healthcare 
to (injecting) drug users. Thus, it is mainly aimed at general practitioners and family doctors, 
substance abuse treatment and rehabilitation centres, correctional healthcare facilities, hospital 
emergency departments and inpatient services. For this reason, the practical guidance on 
voluntary medical examination, testing and counselling for infectious diseases is covered in Part 
1 of this document. Although the guidelines may also be useful in more specialised healthcare 
settings, it should be noted that the recommended tests and follow-up procedures are primarily 
intended as guidance for personnel in primary healthcare settings, and therefore tests and 
procedures considered more appropriate for specialist care are not discussed in detail.
The guidelines can also be used by policymakers, drug use and HIV programme planners and 
coordinators and non-governmental organisations in providing services for drug users. For these 
groups, the recommended methods, background and rationale behind the guidelines, and their 
implementation in health facilities, are described in Part 2.
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Chapter 1
Introduction
Injecting drug users (IDUs) are vulnerable to a range of infectious diseases because of their risk-
taking behaviour and underlying conditions like poor hygiene, homelessness and poverty. These 
include:
HIV infection; ▯
hepatitis A; ▯
hepatitis B; ▯
hepatitis C; ▯
hepatitis D; ▯
skin and soft tissue infections caused by  ▯ Staphylococcus aureus (including methicillin-resistant 
Staphylococcus aureus, MRSA) and streptococcal infections (e.g. endocarditis, necrotising 
fasciitis);
severe systemic sepsis (e.g. infections with  ▯ Clostridium novyi, Bacillus anthracis);
STIs other than HIV or hepatitis (e.g. chlamydial infections, syphilis and gonorrhoea); ▯
respiratory infections such as pneumonia, diphtheria and influenza; ▯
tuberculosis (TB); ▯
wound botulism; ▯
tetanus; ▯
human T-cell lymphotropic virus (HTLV) infections. ▯
This group therefore has higher morbidity and mortality compared with the same age groups in 
the general population. IDUs are more likely than non-injectors or non-users to contract a variety 
of infectious diseases and, when infected, to progress to serious illness and death.
The types of infections more common in IDUs can be divided into blood-borne viral infections, 
bacterial skin and systemic infections, sexually transmitted infections and respiratory infections.
22
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Blood-borne viral infections
The relationship between drug injecting and the transmission of blood-borne viral infections like 
HIV and hepatitis B and C is well established (EuroHIV, 2006; Tefanova et al., 2006; EMCDDA, 
2007; Wiessing and Nardone, 2006). Drug-related infectious diseases such as HIV and hepatitis 
B and C are among the most serious health consequences of injecting drug use. Blood-borne 
infections may have the largest economic impact on healthcare systems of all consequences of 
drug use (Jager et al., 2004). In recent years, some European countries have reported outbreaks 
of hepatitis A among IDUs (Perrett et al., 2003; Blystad et al., 2001; Stene-Johansen et al., 1998). 
Recent studies have shown that hepatitis A is spread among IDUs by fecal–oral transmission, 
contaminated drugs and use of contaminated injection equipment (Stene-Johansen et al., 1998). 
Hepatitis D (delta hepatitis) is relatively rare among the general population in most high-income 
countries and is generally associated with injecting drug use. Hepatitis D can only occur in 
conjunction with hepatitis B infection, and super-infection or co-infection with the hepatitis D virus 
results in more severe complications than infection with the hepatitis B virus alone.
Studies have also shown an association between human T-cell lymphotropic virus (HTLV) 
infections and drug users (Krook and Blomber, 1994). HTLV types I and II can be transmitted 
through breastfeeding, sexual contact, and exposure to contaminated blood through sharing of 
contaminated needles and equipment, with HTLV-II particularly associated with injecting drug 
use. While HTLV-I can cause T-cell leukaemia and T-cell lymphoma, HTLV-II may be involved in 
paraparesis-like neurological disease.
Bacterial skin and systemic infections
IDUs can be exposed to a range of bacteria in various ways that can give rise to local or systemic 
disease (Gordon and Lowy, 2005). Sharing contaminated needles and other drug injection 
paraphernalia, injecting under non-sterile conditions or injecting environmentally contaminated 
drugs are all situations that facilitate the transmission of bacteria. In addition, poor hygiene may 
exacerbate the risk of infection with the drug user’s commensal flora.
Studies have shown that drug users have a higher rate of nasal or skin colonisation with 
Staphylococcus aureus than non-drug users (Kluytmans et al., 1997). Common bacteria like 
Streptococcus or Staphylococcus cause infections that vary in severity from minor skin and soft 
tissue infections to life-threatening disease like bacteraemia/septicaemia, necrotising fasciitis or 
infection of the heart valves (endocarditis) (Wilson et al., 2002). Recently, infection with methicillin 
23
Chapter 1: Introduction
resistant Staphylococcus aureus (MRSA) has been reported as a growing problem in IDUs in 
both Europe and the USA (Fleisch et al., 2001). Cutaneous abscesses and cellulitis at injection 
sites are a frequent problem among IDUs due to subcutaneous or intramuscular injecting (known 
as skin and muscle popping) (Brown et al., 2002; Irish et al., 2007; Binswanger et al., 2000). 
Infections caused by spore-forming bacteria such as Clostridium novyi , Clostridium botulinum, 
Clostridium tetani, Clostridium histolyticum, Bacillus cereus and Bacillus anthracis have in recent 
years emerged as a serious health problem with high mortality rates in IDUs (Akbulut et al., 2005; 
Anon., 2003; Brazier et al., 2004; Brett et al., 2004; Brett et al., 2005; Christopher et al., 2002; 
Hahné et al., 2003; Health Protection Agency, 2006; Jones et al., 2000; Murray-Lillibridge et al., 
2000; Ringertz et al., 2000, Vermeer de Bondt and Vos, 2004).
Acidulant, such as citric acid, is likely to increase the resulting tissue damage when injected 
subcutaneously or intramuscularly, and is therefore a significant cause of wound infections. 
Intravenous injection may be associated with phlebitis or thrombophlebitis, in which the vein may 
be infected.
Drug use can cause significant tooth decay, tooth loss and periodontal diseases. This can be 
attributed to the drugs itself and the lack of a user’s concern about oral hygiene combined with 
drug-induced dry mouth and teeth grinding, as well as a craving for carbohydrates and sweets 
(Robinson et al., 2005). In addition to causing pain and discomfort, oral abscesses and infections 
may be foci for more serious systemic bacterial infections.
Sexually transmitted infections
There is evidence to support an association between drug use and sexually transmitted infections 
(STIs). In a US study of injection drug users, 60 % reported a history of sexually transmitted 
infections (Nelson et al., 1991). Besides HIV infection and hepatitis B, syphilis seems to be the 
most commonly notified STI among IDUs. At the same time gonorrhoea and genital chlamydia 
infections are seen more frequently among IDUs in many European countries (Norbert Scherbaum 
et al., 2005; Hwang et al., 2000). Non-injection drug use can also contribute to STI transmission, 
and the drug most associated with STIs is smokeable freebase (crack) cocaine, because it 
increases risky sexual behaviour and reduces awareness or concern about STIs (Van den 
Hoek, 1997). Injecting and non-injecting drug users who trade sex for drugs or who engage in 
unprotected sex while under the influence of drugs increase their risk of infection.
24
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Respiratory infections
Injecting drug use is associated with increased risk of tuberculosis (TB) infection and disease. This 
is primarily due to high rates of incarceration, homelessness and poverty, all of which are factors 
that increase the risk of TB (Story et al., 2007; Keizer et al., 2000). The immunosuppression 
of HIV infection is associated with an increased risk of TB. The risk of TB in IDUs varies with 
the duration of HIV infection (Van Asten et al., 2003). A study in Amsterdam showed that HIV 
infection increased the risk of active TB in drug users 13-fold. The incidence of TB in HIV-negative 
drug users was still six times higher than in the overall population of Amsterdam (Van Asten et 
al., 2003). In addition, IDUs have an increased risk of TB-reactivation and increased risk of 
developing multi-resistant TB (Jones et al., 1996; Morozova et al., 2003). Lower TB treatment 
completion rates in drug users and in prison settings (often with multi-resistant TB) increase the risk 
of multi-resistant TB in drug users (WHO, 2008a).
Aspiration pneumonia and pneumonia caused by Streptococcus pneumoniae, Haemophilus 
influenzae, Staphylococcus aureus and Klebsiella pneumoniae are among the most common 
reasons for hospitalisation of IDUs (Scheidegger and Zimmerli, 1989; Boschini et al., 1996).  
Some IDUs may be at higher risk of contracting influenzae due to general poor health.
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Chapter 2
Providing medical examination, testing and counselling to IDUs
A thorough medical examination, testing and counselling of IDUs should include:
medical history and physical examination; ▯
pre-test counselling, informed consent and possibility to decline tests; ▯
testing for infections; ▯
post-test counselling; ▯
prevention counselling; ▯
vaccination; ▯
follow-up and referral routines; ▯
frequency of examination and testing; ▯
ethical considerations. ▯
Medical history and physical examination
A thorough anamnesis and physical examination should be carried out, including history of 
present or previous drug injecting and other risk behaviours, and present or previous illnesses 
and symptoms. A thorough medical history should be recorded. Special attention should be given 
during the consultation to the following signs and symptoms:
general: weight loss, physical appearance and temperature; ▯
skin and mucous membranes: anaemia, jaundice, burns, scars, painless eruptions. Look for  ▯
needle tracks or sores on the neck, inside of the trunk, elbows, groin area, penis, legs, feet, 
etc. Injection sites should be inspected for local infections. Inspect the skin and the hairy 
surfaces for skin conditions, e.g. scabies or eczema;
lungs: coughing and abnormal lung sounds could indicate pneumonia. Symptoms such as  ▯
fever, weight loss, night sweats and a cough for more than two weeks may be signs of TB;
28
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heart: blood pressure, heart rate and heart rhythm irregularities, inflammation of the inner  ▯
layer of the heart (endocarditis);
digestive system: infections in oral cavity and dental condition; enlarged spleen and liver; ▯
genitourinary system: amenorrhea, pregnancy, erectile dysfunction, urethral discharge,  ▯
painless chancre, swollen lymph nodes.
Depending on symptoms and clinical findings, the IDU should be referred to specialist care when 
required. This should include a referral to a dentist for tooth extractions and longer-term dental 
care.
Pregnant women should be referred immediately to appropriate antenatal care services. Since 
many pregnant IDUs experience difficulty assessing these services, the healthcare provider should 
make contact with an antenatal clinic in the presence of the client and schedule an appointment.
Pre-test counselling, informed consent and possibility to decline tests
Since the objective of provider-initiated testing and counselling is timely detection of HIV and 
other infections and adequate access to healthcare services, pre-test information can be simplified 
and individual risk assessment and risk reduction measures can be covered during post-test 
sessions. Pre-test information can best be provided individually but if this is not possible group 
sessions may be an alternative. Informed consent should, however, always be given individually in 
private between the client and the healthcare provider and should be recorded by the healthcare 
provider in the patient’s medical file or elsewhere. The IDU should always feel able to decline 
one or more tests without fear for coercion or negative consequences. This is especially important 
in settings where the IDU may feel their freedom of decision is restricted, such as in prisons and 
other closed settings.
Informed consent can be facilitated by adding the following text to an informed consent form and 
reading it out to the client:
‘You are completely free to refuse some or all of the tests, and refusing some or all of the 
tests will have no negative consequences for you. Please could you tick any tests you do 
not want to have and sign that you have understood that you are going to be tested and 
that you are free to decline these tests.’
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Use of this document in a closed setting (prisons and some types of treatment like compulsory 
residential rehabilitation) requires additional training and articulation of the principles of 
confidentiality, voluntariness and counselling.
The provider must ensure that the IDU’s decision-making ability is not impaired by intoxication 
before they choose whether or not to be tested for HIV and other infections.
It is important to provide clients with enough information to enable them to give informed consent. 
They should be told, both orally and in written form:
the reason why testing for HIV and other infections is recommended; ▯
what tests are included; ▯
that the client has the right to refuse them (the client should be allowed to decline some or all  ▯
tests);
about the clinical benefits of testing with regard to treatment possibilities; ▯
that test results will be treated confidentially and will not be shared with anyone without the  ▯
client’s permission;
that declining HIV or other specific tests will not affect the client’s access to services; ▯
that a positive HIV test or positive results from other tests may make it necessary to inform  ▯
partners or others that they may have been exposed to an infectious disease (contact tracing). 
In some countries this may be mandatory and the client must be informed of the existence of 
any such legislation.
Whether or not a client declines an HIV test or other recommended tests, this decision should be 
documented in the medical record. In some situations, documented oral communications may 
be regarded as adequate in obtaining informed consent; however, as described above, it is 
preferable to obtain informed consent in writing.
The healthcare provider should discuss with the IDU how they wish to receive the test results 
before the tests are carried out.
30
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Testing for infections
A medical examination of IDUs should always include voluntary testing for infectious diseases. 
Which test to perform depends on factors such as the IDU’s symptoms or signs and the length of 
time of substance abuse. In addition, the local epidemiological situation among drug users for the 
various diseases should be considered when choosing which tests to perform. Supplementary tests 
may be needed, depending on clinical signs or symptoms.
Providers should ensure that the IDU will have access to suitable treatment of the various infections 
identified by provider-initiated testing and counselling before testing begins. Likewise, efforts 
must be made to ensure that a supportive social and legal framework is in place to minimise the 
potential risks of any negative effects of testing, such as discrimination and stigmatisation. The 
provider should also ensure that mechanisms are in place for referral to care and support services 
provided by community-based organisations and civil society groups. For more detail, see 
Jürgens, 2008 and Jürgens and Betteridge, 2007.
Basic recommended tests
The tests that should be included in a standard offer to all IDUs in provider-initiated routine 
medical examinations are:
Serology testing for: ▯
o HIV;
o hepatitis A;
o hepatitis B;
o hepatitis C;
o hepatitis D (if evidence of chronic or recent hepatitis B);
o syphilis.
Other general blood tests: ▯
o ESR or CRP;
o haemoglobin;
o white blood cell count.
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Swab for culture from abscesses and skin lesions. ▯
Tests for biochemical analysis: ▯
o ALAT (alanine aminotransferase);
o ASAT (aspartate aminotransferase);
o Bilirubin.
Tests for TB disease or latent TB (see comments below). ▯
The need to re-test IDUs who have previously been diagnosed with or are known to have chronic 
infections like HIV infection, hepatitis B or hepatitis C infections should be considered in each 
case. Comments on the various tests are outlined below.
HIV infection
The standard screening test for HIV is a combined HIV-1/2 antibody enzyme immunoassay 
(ELISA) done on venous blood. The fourth generation HIV screening tests detect anti–HIV and 
p24 antigen. A diagnosis of HIV infection cannot be based on a single positive ELISA test alone. 
A positive ELISA test should therefore always be confirmed by a Western blot test in the same 
sample and with ELISA in a subsequent sample collected separately.
Detection of the virus during the ‘window period’ (the period between the onset of HIV infection 
and the appearance of detectable antibodies to the virus) is possible using nucleic acid 
amplification tests (NAAT), like polymerase chain reaction (PCR); however, this will not normally 
be necessary. Modern HIV tests have a high specificity and sensitivity and the window period is 
normally no more than 1 to 2 weeks.
Rapid HIV tests are available in most countries. Use of these tests is often referred to as point of 
care testing (POCT). These tests have the advantage of giving a result within minutes and are used 
on whole blood (e.g. fingerprick) plasma or oral fluid. These tests, however, have slightly lower 
specificity and sensitivity than conventional fourth generation antibody enzyme immunoassay test. 
If such rapid tests are used, all positive results must be confirmed by serological tests.
When to refer: IDUs with a confirmed positive HIV test should be referred to a specialist clinic. 
The care provider and their specialist colleague should try to ensure that the client has an intake 
appointment within one to two weeks of receiving the test result.
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Hepatitis A
Hepatitis A serology should include testing for:
•	 hepatitis	A	IgG	antibody	(anti-HAV	IgG);
•	 hepatitis	A	IgM	antibody	(anti-HAV	IgM)	—	only	in	acute	infections.
The IgM antibody normally develops early in the infection and peaks about one to two weeks 
after the development of jaundice. It diminishes within a few weeks, followed by the development 
of the protective IgG antibody, which persists usually for life. Thus, anti-HAV IgM is a marker of 
acute infection, whereas anti-HAV IgG merely indicates previous exposure to HAV and immunity 
to recurrent infection. Presence of anti-HAV IgG may also indicate previous vaccination. Anti-HAV 
IgM should only be used in cases of suspected acute hepatitis.
Hepatitis B
The diagnosis and stage of infection can be determined from the serology profile. The following 
tests should be included in the panel of hepatitis B tests:
•	 hepatitis	B	surface	antigen	(HBsAg);
•	 hepatitis	B	surface	antibody	(anti-HBs);
•	 hepatitis	B	core	antibody	(anti-HBc	total);
•	 hepatitis	B	core	IgM	antibody	(anti-HBc	IgM).
Interpretation of the tests may be difficult, and is not within the scope of these guidelines. It is 
recommended that a specialist is consulted where there is uncertainty about the test results. The 
window period is four to six months.
When to refer: IDUs diagnosed with acute or chronic hepatitis B (i.e. HBsAg can be detected 
in repeated samples for longer than six months) should be referred to a specialised clinic. Liver 
function status is important when evaluating the need for medication therapy.
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Hepatitis C
The standard screening test is the hepatitis C antibody (anti-HCV) ELISA test. A positive test 
should be confirmed by using a nucleic acid amplification test (PCR-test), or if this is negative with 
a recombinant immunoblot assay, RIBA. A positive antibody test alone is evidence of previous 
exposure to the hepatitis C virus, but gives no indication of whether the virus is still present. The 
window period is four to six months.
Hepatitis D
Hepatitis D should be considered in individuals who are HBsAg positive or who have evidence 
of recent HBV infection. A diagnosis of superinfection or co-infection with the hepatitis D virus is 
made following serologic tests for the virus (total anti-HDV antibodies).
Syphilis
The diagnosis of syphilis in people with early infectious lesions (chancre) is based on clinical 
examination and demonstration of T. pallidum by dark field microscopy, of treponema specific 
DNA by PCR or DFA-TP test (direct fluorescent antibody test for T. pallidum). Serological tests aid 
the diagnosis and are also used for screening in asymptomatic individuals. An important principle 
of syphilis serology is the detection of treponemal antibody by a screening test, followed by 
another reactive screening test for confirmation.
The immune response involves production of specific treponemal antibodies as well as non-
specific antibodies. Various serological techniques allow detection of one or the other, according 
to the particular objectives of screening. Various methods combined enable detection of early 
When to refer: All IDUs with a positive antibody test and a positive PCR should be followed up by 
a repeated test after three to six months, and if the test is still positive, should be considered for 
eradication therapy. Liver function status is important in the evaluation of the need for medication 
therapy.
Specific guidelines exist for the treatment of hepatitis C at national and European level (Hepatol, 
1999). It is important to note that although some guidelines still exclude active IDUs or IDUs on 
opioid substitution treatment from viral treatment, study results indicate that IDUs can be successfully 
treated and may avoid reinfection (Hepatol, 1999; Reimer et al., 2005).
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infections, as well as forms of the infection that were acquired earlier and that have either been 
treated adequately or have remained untreated. Serology may remain positive for life in people 
who have previously contracted syphilis and been adequately treated.
Most laboratories now use specific enzyme-linked immunoassays (ELISA tests) for screening. 
These are newer blood tests that check for treponema-specific IgG and IgM antibodies. A positive 
ELISA test should be followed up by other serological tests, such as the:
TPHA-test (Treponema pallidum haemagglutination test), or often its modified version with  ▯
higher specificity and sensitivity, the TPPA test (Treponema pallidum particle agglutination test). 
Both detect specific antibodies and have high enough sensitivity and specificity to be used 
for either screening or confirmation, and also for monitoring the change in antibody levels 
following adequate therapy.
At the same time, providers often use one of the following tests:
the VDRL test (venereal disease research laboratory test); ▯
the RPR test (rapid plasma reagin test); ▯
the FTA-abs test (fluorescent treponemal antibody absorption test) was a gold standard  ▯
in earlier days that can nowadays be replaced by immunoblotting, and is probably best 
reserved for reconfirming discrepant results.
IDUs, a high-risk group for STIs, need to be screened by (1.) enzyme-linked immunoassay (EIA) 
methods capable of detecting specific antibodies early on, from 10 to 14 days following infection, 
as well as suitable for screening asymptomatic patients and by (2.) equivalent methods such as 
TPHA/TPPA (also able to quantify specific antibodies) as reactive confirmatory methods. The use 
of non-specific methods such as the RPR/VDRL (otherwise ideal methods for screening) in case of 
IDUs is questionable, because of their possible co-infection with HIV.
When to refer: Interpretation of serologic tests for syphilis may be difficult and it is not within the 
scope of these guidelines. Where test results are uncertain, a microbiologist or venereologist should 
be consulted and the patient should be referred to a STI centre.
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Cultures from abscesses and other lesions
A bacteriological test from pus, tissue, or other material properly obtained from an abscess 
or other lesions should be taken and sent to the laboratory for examination using standard 
procedures. A transport medium should be used whenever appropriate. Abscess specimen should 
always be cultured for anaerobes and this should be clearly stated on the request form. Biopsy or 
needle aspirates are the specimen of choice for anaerobic culture, while anaerobic swabs are the 
least desirable. Generally, any specimen should not be stored for more than 24 hours. Specimens 
for anaerobic culture should be stored at room temperature, other specimens at 4 °C.
Tests for biochemical analysis
Optional liver function tests recommended for possible liver function damage are:
ALAT (alanine aminotransferase); ▯
ASAT (aspartate aminotransferase); ▯
bilirubin. ▯
ALAT is an enzyme present in hepatocytes that increases dramatically in acute liver damage, 
such as viral hepatitis. ASAT is similar to ALAT in that it is another enzyme associated with liver 
parenchymal cells. It is raised in acute liver damage, but is not specific only to the liver. The ratio 
of ASAT to ALAT is sometimes useful in differentiating between causes of liver damage. Bilirubin 
is a product that results from the breakdown of haemoglobin. Total and direct serum bilirubin are 
usually measured to screen for or to monitor liver or gallbladder problems.
Tests for tuberculosis
Methods to use in screening for latent or current TB disease depend on the epidemiological 
situation in the country/setting and among IDUs with regard to TB and HIV infection. In addition, 
screening methods depend on the presence of any symptoms of TB disease. Ideally, all IDUs 
should be screened for active TB disease or for latent TB infection.
Sputum smear microscopy, culture and chest X-ray should be used in all European countries and in 
IDUs with symptoms or signs of TB disease (1).
(1) Initially, the IDUs should complete a questionnaire and have a clinical examination to identify the 
presence of signs and symptoms.
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Sputum smear microscopy ▯
 Sputum specimens should be obtained for microscopic examination from all IDUs suspected 
of having pulmonary TB. Microbiological diagnosis is confirmed by culturing Mycobacterium 
tuberculosis (or, under appropriate circumstances, by identifying specific nucleic acid 
sequences in a clinical specimen) from any suspected site of disease. However, in many 
settings where resources are limited, neither culture nor rapid amplification methods are 
currently available or feasible. In such circumstances, the diagnosis of TB may also be 
confirmed by the presence of acid-fast bacilli (AFB) in sputum smear examination. Repeated 
sputum smear microscopy may diagnose pulmonary TB in up to two-thirds of active cases. 
In nearly all clinical circumstances in settings of high TB prevalence, identification of AFB by 
microscopic examination is highly specific for the Mycobacterium tuberculosis complex.
 The optimum number of sputum specimens to establish a diagnosis has been evaluated. The 
first specimen was found positive in 83–87 % of all patients in whom AFB are ultimately 
detected; the second specimen was positive in an additional 10–12 % and the third specimen 
in a further 3–5 %. On this basis, WHO recommends the microscopic examination of two 
sputum specimens (formerly three) (2). Because the yield of AFB appears to be greatest from 
early morning (overnight) specimens, WHO further recommends that at least one specimen 
should be obtained from an early morning collection.
 The procedures for collecting sputum involve the production of droplets that are highly 
infectious if the patient has untreated pulmonary TB. Sputum collection should therefore be 
organised in areas with good ventilation or, if not available, outside the building. Sputum 
smear specimens should be examined by microscopy immediately but no later than five to 
seven days after they have been collected.
Culture ▯
 Sputum smear microscopy is the first bacteriological diagnostic test of choice. However, where 
adequate and quality-assured laboratory facilities are available, the evaluation of patients 
should also include culture. Culture adds extra cost and complexity but greatly increases the 
sensitivity and specificity of diagnosis, resulting in better case detection. Although the results 
of culture may not be available until after a decision to begin treatment has been made, 
treatment may be stopped subsequently if cultures from a reliable laboratory are negative 
(2) A reduction in the number of specimens examined for screening TB suspects from three to two was 
recommended by WHO and endorsed by the Strategic Technical and Advisory Group for Tuberculosis 
in June 2007.
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and if the patient has not responded clinically to treatment and the clinician has sought other 
evidence in pursuing the differential diagnosis.
Chest X-ray ▯
 As no chest radiographic pattern is absolutely specific for pulmonary TB, the diagnosis 
of smear-negative TB is always presumptive and should be based on other clinical and 
epidemiological information, including failure to respond to a course of broad-spectrum 
antibiotics and exclusion of other pathology. Reliance on chest radiography as the only 
diagnostic test for TB results in either overdiagnosis of TB or missed diagnoses of TB and 
other diseases and is therefore not recommended. Radiographic examination, however, 
is most useful when applied as part of a systematic approach to evaluate patients whose 
symptoms and/or findings suggest TB but whose sputum smears are negative. The use of 
chest radiography to diagnose pulmonary TB may be compromised by poor film quality, low 
specificity and difficulties with interpretation.
 HIV infection diminishes the reliability of chest radiographs for the diagnosis of pulmonary 
TB because the disease commonly presents with an atypical pattern. Furthermore, the chest 
radiograph may be normal in a proportion of HIV-infected patients with sputum culture-
positive TB (observed in up to 14 % of such cases). Chest radiography remains an important 
adjunct to the diagnosis of smear-negative pulmonary TB in people living with HIV.
 Fluoroscopy results are not acceptable as documented evidence of pulmonary TB.
 Sputum smear microscopy and culture require skill and experience by the healthcare provider. 
If healthcare providers who are doing the medical examination, testing and counselling 
for infectious diseases in IDUs do not have the necessary skill, or the appropriate safety 
precautions are not in place, TB screening should not be a part of the basic screening test and 
all IDUs should be referred for TB screening to competent health institutions.
 The screening procedures in IDUs with no signs or symptoms of TB disease can be limited to 
screening for latent TB. The screening methods for latent TB in asymptomatic IDUs include the 
tuberculin skin test and blood tests.
The tuberculin skin test (TST) ▯
 This skin test has traditionally been used to diagnose latent infection with Mycobacterium 
tuberculosis. However, it has several limitations, particularly poor specificity because of cross-
reactivity with the antigens of the Bacille Calmette Guérin (BCG) vaccine, as well as many of 
the nontuberculous mycobacteria. In addition, false-negative TST is more likely to occur among 
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IDUs because of the high rate of anergy that occurs in this population, most commonly found 
in HIV-seropositive IDUs. For this reason, less emphasis should be put on TST results in IDUs 
in areas where HIV prevalence in this group is high, and more on potential exposure to TB 
together with signs and symptoms of the disease.
Blood tests ▯
 IFN-gamma release assays (IGRA tests) have in recent years been proposed as alternatives 
to the TST. The potential for false-positive tests due to cross-reactivity is significantly lower 
with IGRAs than with the TST. In addition, the use of this test in IDUs is more likely to diagnose 
latent TB infection compared with traditional TSTs (Grimes et al., 2007). However, IGRAs have 
as yet limited potential in high burden TB and HIV settings.
Additional recommended tests
In addition to the recommended basic panel of tests, testing for other blood and sexually 
transmitted infections may be indicated depending on the local epidemiological situation and the 
condition of the individual IDU. The additional panel of tests recommended in provider-initiated 
routine medical examination are:
serology for HTLV-infections; ▯
swab or urine testing for genital chlamydial infections; ▯
swab or urine testing for gonorrhoea. ▯
When to refer: IDUs with symptoms or signs of active pulmonary tuberculosis as well as IDUs with 
positive bacteriological results (sputum smear microscopy or culture) or X-ray findings consistent with 
suspected TB disease should immediately be referred to a TB clinic or other specialists for further 
examination, diagnosis and treatment.
Asymptomatic IDUs with a positive TST or IGRA test, in which TB as a disease is excluded should be 
considered for TB preventive therapy and referred to a specialist. Anergic HIV-seropositive people 
who come from a population with a high prevalence of TB infection should also be considered for 
preventive therapy and therefore referred to a specialist.
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Such tests should be carried out in both sexes in case of IDUs reporting commercial sex work. 
Studies have shown that the presence of a sexually transmitted disease may facilitate transmission 
of HIV (Sexton et al., 2005).
Genital chlamydial infections
Asymptomatic chlamydial infection is common among both men and women, and to detect 
chlamydial infections, healthcare providers frequently rely on screening tests. Nucleic acid 
amplification tests (NAAT) for Chlamydia trachomatis are currently the preferred tests for genital 
chlamydial infections and are widely used. The advantage of these tests is that they are generally 
more sensitive and specific than a conventional culture and can therefore identify more positive 
specimens. Recommended specimens used for NAATs are first catch urine in men and swab of the 
vaginal introitus or urine in women.
Gonorrhoea
IDUs presenting with symptoms of urethritis should have a swab test of secretion or discharge from 
the infected area such as the cervix, urethra, glans of penis, anus or throat. This specimen should 
be both cultured and tested for antibiotic susceptibility. NAAT tests such as PCR are available for 
testing swabs as well as female and male urine. Some NAATs have the potential to cross-react 
with non-gonococcal Neisseria and related organisms that are commonly found in the throat.
Since so many gonorrhoeal infections are symptomatic, screening for gonorrhoea in 
asymptomatic individuals is rarely indicated. If the local epidemiological situation among IDUs 
(e.g. an outbreak) should favour screening of asymptomatic individuals, endocervical swabs 
or male urethral swabs should be collected and cultured. Alternatively, NAAT testing on urine 
samples could be used if available.
HTLV infection
HTLV infections are diagnosed using combined HTLV-I/HTLV-II antibody ELISA tests and they are 
confirmed by a Western blot test where one can decide if it is a HTLV-I or HTLV-II virus, the latter 
being frequently positive in IDUs.
Post-test counselling
Post-test counselling is an important and integral part of the testing process. All clients must be 
counselled when the test results are given, regardless of the outcome of the tests. The results 
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should be given in person by a healthcare provider or other trained personnel, and ideally by the 
same healthcare provider who initiated testing and counselling. If for some reason the client does 
not show up to the follow-up consultation, the healthcare provider should make every reasonable 
attempt to ensure that they receive and understand the test results in a confidential manner. All 
available channels should be considered in trying to contact the client, with the involvement of 
social services. Written information about test results should never be sent to the client unless 
specifically agreed on prior to testing. Results of tests should not be given via any third party, 
including relatives or other clinical teams, unless the IDU has specifically agreed to this.
The focus of post-test counselling should be on positive results. In particular, a client with a positive 
HIV test result should be given psychosocial support to enable them to cope with the emotional 
impact of the test result. Elements to be included in post-test counselling are:
ensure that the client understands the results; ▯
ensure that in a case of hepatitis, syphilis or TB, the client understands the difference between  ▯
acute infection, chronic infection and past infection, possible longer-term consequences and 
whether he/she can transmit the disease to others;
describe the follow-up services that are available in healthcare facilities and in the community,  ▯
with special attention to available treatment and care and support services including non-
governmental support groups;
describe in detail how to prevent further transmission of the various diagnosed diseases; ▯
provide information on other health issues related to the test results, such as nutrition; ▯
encourage testing and counselling of recent sexual partners or, if relevant, family members,  ▯
and offer referral. If possible, in the follow-up process the client should be offered support 
for disclosure and couples counselling. Testing, treatment and vaccination of partners and 
children may be necessary;
provide information on the possibility of post-exposure prophylaxis with regard to relevant  ▯
infections (e.g. HIV infection and hepatitis B);
plan follow-up and referral to specialised health services or clinics, and shortly thereafter  ▯
arrange for an appointment to be scheduled for the client with those services soon;
briefly check that the key issues have been understood by asking the client to repeat the main  ▯
points that have been discussed;
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give the client a clearly written (or pre-existing) memo with a summary of those points and any  ▯
relevant contact details, and explain that they can re-contact you (the healthcare provider) if 
they have doubts or new questions.
Individuals who test HIV negative should be offered advice about risk reduction and behaviour 
changes, including a discussion relating to post-exposure prophylaxis (PEP) for HIV. The need for 
a repeat HIV test should also be considered if the client is still within the window period. A repeat 
HIV test is recommended at three months following a specific exposure.
Prevention counselling
During the examination and testing process the client should be given individual general 
information on how to reduce the risk of acquiring drug-related infections and sexually transmitted 
infections. Ideally, this information should be provided at the follow-up visit when the results of 
tests are given. Some IDUs, however, will not turn up to the follow-up visit and information, or part 
of it, is often best (also) given within the pre-test discussion. Client-centred prevention counselling 
involves tailoring a discussion of risk reduction to the patient’s individual situation.
Reducing or stopping the use of drugs is the safest way to prevent drug-related infectious 
diseases. This goal, however, may not always be realistic and counselling should therefore include 
information on how to reduce the risk of acquiring infections (see box).
Information for injecting drug users on the prevention of blood-borne 
and bacterial infections
•	 Always	use	a	new	(sterile)	needle	and	syringe	every	single	time	you	inject.	Syringes	and	needles	
are not designed to be used more than once.
•	 Never	share	needles,	syringes,	water,	cooker,	filters	or	cotton	with	anyone.
•	 Never	re-use	needles,	syringes,	water,	cooker,	filters	or	cotton.
•	 If	you	are	sometimes	forced	to	re-use	or	share	needles	and	syringes,	clean	them	thoroughly	each	
time. Follow these steps to clean a needle or syringe:
1. Clean the needle and syringe (twice) with cold running tap water to remove blood, blood clots, 
and other organic material.
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2. Disinfect them with bleach (twice): 30 seconds’ exposure to undiluted household bleach is the 
best way to eradicate viable HIV (Abdala et al., 2001).
3. Rinse them in clean running tap water (twice) to remove the bleach.
 Alternatively, clean the needle and syringe thoroughly under running tap water, then cook them 
for 10 minutes.
•	 If	re-using	the	cooker,	clean	it	thoroughly	every	time	by	cooking	in	boiling	water	for	10	minutes,	
or clean it with isopropyl alcohol (alcohol prep/swab).
•	 Use	clean	water	to	prepare	your	injection.	Use	either:
o water boiled for five minutes in a clean pan;
o cold running tap water;
o a newly opened bottle of mineral water or soda pop/fizzy drink.
•	 Improve	safer	injection	practices:
1. Wash hands before and after injecting (especially when helping others).
2. Boil the drug if possible.
3. Clean the skin before injecting with alcohol or any other disinfectant solution.
4. Avoid the use of dangerous injection sites such as the neck and groin.
5. Avoid injecting under the skin or directly into a muscle.
6. Clean all materials used, including the table surface, with disinfectant.
•	 If	available,	use	treatment	facilities	and	harm	reduction	measures	such	as:
o needle exchange programmes and other sources of sterile injecting materials (e.g. 
pharmacies) ─ ask for enough equipment to avoid having to re-use anything;
o drug-assisted rehabilitation or opioid substitution programmes (e.g. methadone programmes 
or other drug treatment services);
o medically supervised injection facilities.
•	 Try	to	reduce	or	stop	using	drugs.	Replace	injecting	practices	with	non-injecting	practices	such	as	
smoking and sniffing, and if possible, reduce the frequency of injecting.
•	 Avoid	unprotected	sex	─	always	use	a	condom,	and	avoid	or	reduce	sex	with	multiple	partners.
•	 Improve	your	personal	hygiene,	especially	oral	hygiene.
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The provider should be familiar with what resources are available within the local community. 
During the consultation, the client should be given any available written information on preventive 
measures (folders, leaflets, brochures).
Vaccination
Vaccination against drug-related infections should, if available, be offered to the clients. Which 
vaccines to offer depends on the country’s vaccination programme (including potential specific 
programmes for IDUs), on any documentation regarding previous vaccination or on the results 
of tests carried out at the first consultation. Self-reported vaccination status is usually unreliable 
and the decision on what vaccines to offer should not be based on self-reporting. A plan 
should be made in consultation with the client for the provision of additional or booster doses. 
Recommended vaccines for IDUs are:
hepatitis A and B combination vaccine (or separate hepatitis A and hepatitis B vaccines); ▯
diphtheria/tetanus vaccine (every 5 to 10 years); ▯
influenzae vaccine (seasonally); ▯
pneumococcal vaccine (especially if HIV positive and >50 years of age). ▯
Hepatitis A and B combination vaccines or separate hepatitis B vaccine can be administered 
as a three-dose schedule at zero, one and six months or as a four-dose schedule administered 
on days zero, seven and 21 followed by a booster dose at month 12. The rate of non- or low 
responders to the vaccine is higher in drug users, especially those infected with HIV, than in the 
general population. It is therefore recommended to test for antibody to hepatitis B surface antigen 
(anti-HBs) one to two months after completing the third dose of the vaccine series. In cases of low 
antibody titre, additional booster dose(s) may be needed.
BCG vaccination against TB should be considered, depending on the country’s BCG vaccination 
programme policy.
Human papillomavirus (HPV) vaccine targets certain sexually transmitted strains of human 
papillomavirus associated with the development of cervical cancer. HPV strains covered by the 
vaccine are normally acquired soon after onset of sexual activity, and HPV vaccine should ideally 
be given to girls at the age just before sexual debut. HPV vaccination should be considered for 
female IDUs, depending on the country’s HPV vaccination programme policy.
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In general, depending on the cost of the vaccine, it may be more cost-effective to provide a 
standard vaccination offer to IDUs rather than allowing the decision to depend on serological 
results or self-report, and given the difficulty of maintaining contact with IDUs for follow-up 
vaccination (de la Fuente et al., 2007).
Vaccinations should in general be avoided during pregnancy.
Follow-up, treatment and referral routines
Any diagnosed localised skin infections or other minor infections, pneumonia or sexually 
transmitted diseases (such as gonorrhoea or genital chlamydial infections) should be treated 
during the routine examination process.
Conditions that need specialist follow-up and care (such as HIV infection, TB, hepatitis and 
syphilis) should be referred to competent clinics or specialist services. Patient referral works best 
if the healthcare provider makes contact with the specialist in the presence of the client and 
schedules an appointment. Where possible, primary health services and specialist care should 
be located near each other and/or be linked through case-based management where primary 
service providers and different specialists (e.g. drug treatment and infectious diseases treatment) 
work together and keep each other informed regarding the patient.
Frequency of examination and testing
The recommended frequency of routine medical examination, testing and counselling in IDUs 
depends on various factors, such as the local epidemiological situation of HIV infection or other 
infections, and the availability of human and financial resources. In addition, the frequency with 
which a client should be re-examined and re-tested depends on the individual risk of exposure 
to infectious agents. For individuals who are ongoing injecting drug users or involved in ongoing 
high-risk sex (e.g. sex work or male-to-male sex with multiple partners) this risk is usually very high 
(it should be noted that a client may intentionally or unintentionally under-report the frequency 
of risk behaviours) and frequent re-examination and re-testing are recommended to reduce the 
period of undiagnosed carriership after infection and thus the risk of infecting others. For practical 
reasons and taking into account these considerations, it is recommended that examination and 
testing is offered to IDUs at least once every six to 12 months.
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Ethical considerations
(See also the section ‘Pre-test counselling, informed consent and possibility to opt-out’, page 28.)
The provider must ensure that the drug user’s decision-making ability is not impaired by 
intoxication before they discuss and decide on testing for HIV and other infections.
Patients should receive adequate information enabling them to make a personal and voluntary 
decision whether or not to decline one or all of the proposed tests without coercion.
Confidentiality must be strongly enforced with regard to test results and information obtained 
during the examination. However, this must not prevent the provider from documenting findings in 
the patient’s medical record. It is recommended that the offer of an HIV test is recorded explicitly, 
and that informed consent and pre- and post-test counselling have taken place; where a client 
refuses a test, a note of the reasons for their refusal should be made in their records. Such medical 
records should only be accessible to those (other healthcare providers) who have a direct role 
in the ongoing management of the patient. Administrative personnel at institutions (e.g. prisons) 
should never have access to a patient’s health records.
It is the healthcare provider’s responsibility to ensure that the examination and testing will not 
result in any harm or negative effects to the IDU. This includes ensuring that the police or other 
authorities do not keep the examination/testing site under surveillance. In situations where these 
conditions are likely not to be met it is recommended that provider initiated testing is refrained 
from, and voluntary counselling and testing is made available at the individual’s request, while 
making sure that individuals are well aware of this possibility.

PART TWO
Background and implementation  
of the guidelines
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Existing guidelines and the need for separate guidelines for IDUs 
The main existing guidelines on HIV testing and IDUs are:
Guidance on provider-initiated HIV testing and counselling in health facilities (WHO, 2007)  ▯
This document offers basic operational guidance on provider-initiated HIV testing and 
counselling in health facilities on a global basis. The document is consistent with WHO policy 
options developed in 2003 and with a 2004 UNAIDS/WHO policy statement on HIV 
testing (UNAIDS and WHO, 2004), although it states that for highly vulnerable populations, 
an opt-in approach may merit consideration. The guideline addresses the testing of IDUs at 
needle and syringe access points, and other harm reduction interventions including referral to 
opioid substitution therapy. It recommends testing higher risk individuals every 6 to 12 months, 
depending on the epidemic situation. However, the guidelines have no specific section on 
testing in IDUs.
Guidance on testing and counselling for HIV in settings attended by people who inject drugs  ▯
(WHO and UNODC, 2009) 
This document offers basic operational guidance on HIV testing and counselling in settings 
attended by people who inject drugs. HIV testing is recommended for all patients whose 
clinical presentation might result from underlying HIV infection and as a standard part of 
medical care for all patients attending specialised healthcare facilities for people who inject 
drugs. The document recommends a proactive approach to HIV testing and counselling by 
care providers in these settings. It includes simplified pre-test information consistent with WHO 
and UNAIDS policy. Individuals offered an HIV test must specifically accept or decline the test 
after discussion of their right to decline, the risks and benefits of HIV testing and disclosure, 
and the social support available.
Revised recommendations for HIV testing of adults, adolescents and pregnant women in  ▯
healthcare settings (Centers for Disease Control and Prevention, 2006b) 
The objective of these recommendations is to increase HIV screening of patients in healthcare 
settings, including substance abuse treatment clinics and correctional healthcare facilities. The 
recommendations do not apply to non-clinical outreach programmes or community centres. 
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In these guidelines HIV screening is recommended for all individuals aged 13 to 64 in all 
healthcare settings following notification to the patient that the testing would be performed 
unless the patient declines (opt-out screening). It is recommended that people at high risk of 
HIV infection (like IDUs) should be screened for HIV at least annually. More controversially, 
the document states that separate written consent for HIV testing should not be required and 
that prevention counselling should not be required with HIV diagnostic testing or as part of 
HIV screening programmes in healthcare settings. Although these recommendations mentioned 
IDUs as a high-risk group who should be offered annual HIV testing, there is no specific 
information about testing IDUs.
Policy and programming guide for HIV/AIDS prevention and care among injecting drug users  ▯
(WHO, 2005) 
This guide concentrates on distilling the principles from policies and programmes that have 
worked well in responding to HIV/AIDS epidemics among IDUs. It emphasises that the issues 
involved in developing and sustaining effective responses to HIV/AIDS and injecting drug 
use are complex, and every society and community is different. How these principles are 
expressed in a specific society depends on the characteristics of that society. The guide aims 
to help people in applying principles that have proven to be effective in dealing with HIV/
AIDS and injecting drug use. HIV testing and counselling is mentioned as an integral part of 
a comprehensive prevention approach, links to other interventions are emphasised, but little 
detail is provided on issues around HIV testing in IDUs.
Policy guidelines for collaborative TB and HIV services for injecting and other drug users —  ▯
an integrated approach (WHO, 2008b) 
WHO has, in cooperation with UNODC and UNAIDS, and in consultation with a group 
of technical experts, published policy guidelines for collaborative HIV and TB services for 
injecting users and other drug users in general. The aim of this guidance is to provide a 
strategic approach to reducing TB- and HIV-related morbidity and mortality among drug users 
and their communities, in a way that promotes holistic and person-centred services.
In addition, UNODC/WHO/UNAIDS have developed specific guidance on ‘HIV testing and 
counselling for people who use drugs’ and on ‘HIV testing and counselling in prisons and other 
closed settings’. These background papers, which will serve as the basis of a policy statement on 
HIV testing and counselling, propose that an opt-in approach to HIV testing should be considered 
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for these most-at-risk populations, given the risks of coercion, discrimination or other negative 
consequences and confidentiality breaches (Jürgens, 2008; Jürgens and Betteridge, 2007).
Similar to IDUs, men who have sex with men (MSM) are a population most at risk of acquiring 
HIV in addition to other sexually transmitted infections. In 2006, the Centers for Disease Control 
and Prevention published the document ‘Sexually transmitted disease treatment guidelines 
2006’ (Centers for Disease Control and Prevention, 2006a). In this document, routine laboratory 
screening for common sexually transmitted diseases is recommended for all sexually active 
MSM. These tests are recommended to be performed at least annually for sexually active MSM, 
including men with or without established HIV infection. Similar recommendations for routine 
testing in MSM have been published in Australia and in Norway (Blystad and Klouman, 2005). In 
the UK, national guidelines for HIV testing were published in 2008 by the British HIV Association. 
These guidelines are intended to facilitate an increase in HIV testing in all healthcare settings in 
order to reduce the proportion of individuals with undiagnosed HIV infection. The guidelines stress 
that HIV testing should remain voluntary and confidential, and that universal opt-out testing in 
all settings may not be the most feasible approach, but they support the use of opt-out testing in 
certain situations (British HIV Association, 2008).
IDUs have specific needs and encounter specific challenges for testing, care and treatment, 
warranting particular approaches for the group. Lack of testing uptake in IDUs may have serious 
consequences for the prevention of further spread of HIV and other infections, as well as for 
the early treatment and care of those infected, and the quality of diagnostic surveillance data 
regarding this group.
Efficient testing approaches need to include testing combining with low-threshold drug services, 
including opioid substitution treatment, care and antiretroviral treatment. Most existing guidelines 
on HIV testing do not cover the special needs of IDUs satisfactorily and there is a lack of 
guidance on other infections, many of which (e.g. viral hepatitis) are highly prevalent among 
IDUs. It appeared therefore timely that separate guidelines for testing HIV and other infections 
in IDUs were developed. These guidelines should integrate HIV testing into a standard provider-
initiated offer to IDUs of voluntary and confidential medical examination that also includes testing 
for other infections, counselling and preventive measures like vaccination as well as referral to 
specialist services. In addition, improving testing uptake for HIV and other drug-related infections 
will improve the general health situation of the individual IDU and is likely to lower the risk of 
secondary spread from infected individuals.
Chapter 3: Background
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Recommendations at policy level to create and ensure the necessary 
conditions for provider-initiated testing for IDUs (1)
A number of important recommendations can be drawn from the general guidelines mentioned 
above and draft documents currently being developed by UNODC/WHO/UNAIDS that are 
relevant for the present document and should be considered by national and local policymakers 
when considering implementation of provider-initiated testing for IDUs. These are:
Implementation must include measures to prevent compulsory testing and unauthorised  ▯
disclosure of results.
Implementation should be accompanied by the comprehensive package of prevention and  ▯
care for IDUs (e.g. needle and syringe programme, opioid substitution treatment, antiretroviral 
therapy, etc.) (WHO, UNODC and UNAIDS 2009).
If antiretroviral therapy (ART) is not available there must be a reasonable expectation that it  ▯
will become available for all who need it.
A supportive social, policy and legal framework must be in place to maximise effects and  ▯
minimise harms.
Training and supervision should be provided for staff to enable them to uphold ethical  ▯
standards.
Additional discussion may be needed on the client’s right to decline testing. ▯
Referral mechanisms should be reviewed and optimised. ▯
If conditions for provider-initiated approaches are not met, testing should instead be made  ▯
available for highly vulnerable populations at the individual’s request.
Most at-risk populations or their representatives (e.g. non-governmental organisations) should  ▯
be involved in protocol development and monitoring.
Before implementing provider-initiated testing, countries should develop clear plans and  ▯
pilot projects to evaluate and address possible coercion, discrimination or other negative 
consequences of disclosure of HIV status.
(1) Adapted from Jürgens and Betteridge, 2007 and WHO, 2005.
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Provider-initiated voluntary medical examination, testing and counselling
These guidelines recommend a provider-initiated approach to voluntary (informed consent based) 
and confidential medical examination, testing and counselling of IDUs, provided the conditions for 
safe and ethical implementation are met. Where this is not the case (e.g. in prisons or other closed 
settings), testing should be limited to making voluntary counselling and testing available at the 
individual’s request.
Provider-initiated
Provider-initiated means that examination, testing and counselling is recommended by a 
healthcare provider as a standard component of medical care offered to people attending the 
facilities. The person involved may attend the facility for a variety of reasons, for instance specific 
medical or other health problems, rehabilitation, use of harm reduction services or through social 
and economic need. The objective of provider-initiated testing is to identify specific infections in 
people at a high risk of contracting HIV and other infections. In addition, suspected infections can 
be confirmed in individuals with specific signs or symptoms. This strategy is not new in relation 
to testing injecting drug users for HIV. Ever since injecting drug users were recognised as a most-
at-risk population for HIV in the early 1980s, national health authorities have actively promoted 
provider-initiated voluntary HIV testing in settings such as prisons, health or rehabilitation centres 
where IDUs are being contacted by health or social services, and through harm reduction 
programmes or different types of outreach. IDUs have for many years been regarded as a target 
group for such opportunistic testing approaches, since in contrast to other most-at-risk populations 
(e.g. MSM) IDUs have been seen as a harder to reach group within the traditional health systems.
Many European countries have introduced provider-initiated HIV testing and counselling in 
prenatal care. Such programmes have resulted in considerable increases in HIV testing uptake in 
Europe and elsewhere, including the United States, the United Kingdom, Norway and Canada 
(Obermeyer and Osborn, in press).
Opt-out versus opt-in approaches
Different guidelines have taken different standpoints regarding opt-out or opt-in strategies. 
Published literature suggests that the testing uptake is increased where universal routine  
(‘opt-out’) strategies have been adopted (Simpson et al., 1998; Haukoos et al., 2008).  
An opt-out testing strategy stresses that testing is a standard part of medical care and that the 
individual must specifically decline testing for some or all infective agents following pre-test 
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counselling. It must be emphasised that in an opt-out approach no tests should be done against  
a person’s wishes or without his/her knowledge. In an opt-in approach clients are offered testing, 
and if they agree, they must provide explicit consent once they have received pre-test information.
In these guidelines, we have chosen to refrain from using the terms ‘opt-in’ or ‘opt-out’, as it 
became clear that some confusion still surrounds these terms. In addition, it seems evident that 
an opt-out approach can be well coupled with informed consent and counselling and may not in 
practise differ much from an opt-in approach.
In a policy statement of HIV testing published by WHO and UNAIDS in 2004, four types of HIV 
testing were clearly distinguished (UNAIDS and WHO, 2004):
voluntary counselling and testing based on a client’s initiative; ▯
diagnostic HIV testing (when there are symptoms or following exposure); ▯
routine offer of HIV testing by healthcare providers; ▯
mandatory HIV testing. ▯
Of these four types of testing approaches, all but mandatory HIV testing is recommended for 
testing IDUs. The EMCDDA, like the UNODC, WHO and UNAIDS, does not support compulsory 
or mandatory testing of individuals on public health grounds.
Populations that are most at risk, such as IDUs, may be more susceptible to coercion and 
discrimination upon disclosure of their HIV status and their status regarding other viral and 
bacterial infections. In addition, for an IDU who is admitted to a health institution, disclosure of 
acute or chronic bacterial infections like TB or an infection with methicillin-resistant Staphylococcus 
aureus (MRSA), subject to general hospital hygiene regulations, may result in strict contact 
precautions and isolation. The conditions under which IDUs undergo testing for HIV and other 
infections must therefore be anchored in a human rights approach and follow ethical principles, 
and healthcare providers must follow the highest standards with regard to confidentiality and 
unauthorised disclosure of test results.
Rationale for provider-initiated medical examination and testing in IDUs
Many of the infections that are more common in IDUs as compared to non-users are asymptomatic 
and the individual will in general benefit from knowing their status for these infections. If 
diagnosed, most of these conditions can be treated and infection control measures can prevent 
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further spread of the disease. Most IDUs are familiar with injection-related diseases and are often 
able to recognise signs and symptoms of their illnesses. Nevertheless, only a minority of IDUs seek 
the necessary medical or prophylactic treatment. Provider-initiated voluntary examination, testing 
and counselling is expected to:
improve the general health of the individual IDU; ▯
improve testing uptake for HIV and other drug-related infections; ▯
increase access of IDUs to treatment for HIV and other infections; ▯
improve diagnosis of chronic infections that need specialist care; ▯
increase vaccination coverage in IDUs; ▯
improve access of IDUs to prevention counselling and information; ▯
improve surveillance of HIV, hepatitis and other drug-related infections in IDUs. ▯
HIV testing uptake by IDUs
One of the objectives of these guidelines is to increase the uptake of HIV testing by IDUs. 
Available data suggest that at the end of 2006 the transmission of HIV among IDUs was low 
in most countries of the European Union and Norway (Jürgens, 2008; Tefanova et al., 2006; 
Haukoos et al., 2008; ECDC and WHO, 2007). This may at least partly follow from the increased 
availability of prevention, treatment and harm reduction measures, including substitution treatment 
and needle and syringe exchange programmes, although other factors, such as the decline 
in injecting drug use observed in several countries, may also have played an important role. 
However, less is known about the proportion of IDUs with HIV who are unaware of their HIV 
status. For several EU countries and regions it is likely that IDU-related HIV transmission has 
continued at relatively high rates.
Since the beginning of the HIV/AIDS epidemic in the early 1980s, HIV testing in populations most 
at risk has been regarded as a key part of the prevention strategy. Several studies have shown 
that IDUs who know their HIV serostatus might reduce their risk behaviour, especially if diagnosed 
HIV positive (Desenclos et al., 1993). In addition, since effective antiretroviral treatment became 
available in the mid 1990s, knowledge of HIV status is critical for expanding access to successful 
treatment, care and support in a timely manner.
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Some studies on testing uptake based on sentinel surveillance with large IDU samples have been 
carried out in EU countries. A study from Estonia in 2005 showed that 90 % of the examined IDUs 
had ever been tested for HIV and 62 % had been tested the previous year (Uusküla et al., 2006). 
In the UK, 30 % of IDUs who took part in a survey reported never having had a voluntary test for 
HIV. Of those who had antibodies to HIV, 64 % were aware of their infection (Health Protection 
Agency, 2007).
Summary of research findings regarding HIV testing and counselling in 
people who use drugs (2)
It is not within the scope of this document to provide a review of research on HIV testing and 
counselling, so for more detail and references the reader is referred to Van den Hoek (1997), 
Centers for Disease Control and Prevention (2006b), and the EMCDDA. The main findings can be 
summarised as follows:
Many drug users are not aware of their HIV serostatus (in Europe perhaps 30–50 %) and this  ▯
figure is likely to be higher for other infections such as hepatitis C.
Reported rates of HIV testing vary widely in Europe. ▯
Drug users have inequitable access to highly active antiretroviral treatment as compared to  ▯
other risk groups, whereas access to HCV viral treatment is generally low.
Staff attitudes to drug users, resulting in stigma and discrimination, may be a major barrier to  ▯
accessing health services.
Outreach, mobile testing vans, peer outreach and anonymous testing sites have been  ▯
recommended as alternative testing delivery options.
Improved HIV testing uptake may result from providing additional services (needle and syringe  ▯
programmes, opioid substitution treatment) and additional testing, such as for hepatitis C.
IDUs are more likely to delay testing and fail to return for test results than other groups, but if  ▯
they do return for results they may be more likely to enter treatment, if required.
(2) Adapted from Jürgens and Betteridge, 2007 and WHO, 2005.
57
Chapter 3: Background
Factors related to testing or returning for test results can work either in a positive or negative  ▯
direction: 
─  Positive factors include: knowledge about HIV/AIDS; convenience of access to the testing 
site; risk perception; education; desire to protect oneself or others; support from others; 
monetary incentives; the perception that having HIV is a problem.
─  Negative factors include: fear about possible positive results; fear of police, medical 
staff, employer or others; fear of needles and difficulty drawing blood; frequency of drug 
injecting; perceived lack of confidentiality; limited access to treatment; desire not to know 
one’s status; drug use taking precedence over self-care; a negative test result by the sexual 
partner; recently having had a test; costs.
Testing is often coercive in low- and middle-income countries and is often associated with  ▯
serious confidentiality problems.
There is little or mixed evidence of a reduction in risk behaviour in IDUs (sexual or injecting  ▯
risk).
Predictors for continued risk include poor health, lack of social support, low level of  ▯
knowledge. Coping mechanisms may play an important role as well.
There is little evidence on whether testing increases prevention and care uptake in IDUs, and  ▯
delays in onward referrals are a significant barrier.
In low- and middle-income countries, legislation often hampers prevention access, e.g.  ▯
syringe prescription or drug paraphernalia laws, or illegal classification of opioid substitution 
treatment.
HIV and HCV testing can be successfully implemented in low-threshold needle and syringe  ▯
programmes and is readily used even if other testing sites are available.
Combining voluntary counselling and testing with other services such as opioid substitution  ▯
treatment results in higher willingness to test, high testing rates and return rates, higher access 
to services, including for cocaine users, while no adverse effects are found on drug treatment 
outcomes.
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Implementation
Heath facilities
Ideally, all health facilities should be able to offer provider-initiated voluntary medical 
examination, testing and counselling for infectious diseases to IDUs. However, health providers 
must have the necessary knowledge and skills to be able to provide IDUs with satisfactory health 
services.
Suitable settings for implementation
The facilities most suitable for offering provider-initiated voluntary medical examination, testing 
and counselling for infectious diseases to IDUs are:
primary healthcare, including general practitioners and family doctors; ▯
special health services for IDUs delivered through mobile clinics, in other community settings,  ▯
through harm reduction programmes or through other types of outreach;
low threshold service centres visited by IDUs; ▯
prison healthcare facilities; ▯
rehabilitation centres and other drug treatment services; ▯
sexual health clinics; ▯
infectious diseases clinics; ▯
tuberculosis clinics (in countries with a high incidence of tuberculosis among IDUs). ▯
Clinicians and other health professionals should assess the risks of drug use-related infections 
among patients or clients, including a non-judgemental standard inquiry about drug habits and 
use. Sufficient time should be made available for individual consultations.
The specific case of prisons and other closed settings
As discussed throughout this document, specific attention is needed to safeguard patients’ rights 
and avoid coercion or misuse of test results in prisons and other closed settings (Jürgens, 2008). 
4
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Yet it is important that such settings do provide ethically high standard healthcare and services, 
including voluntary counselling and testing for HIV and other infections.
EU policy guidance on this point is currently in development. The revised European Prison Rules 
published by the Committee of Ministers of the Council of Europe in 2006 state that prisoners are 
entitled to a medical examination at the point of first admission (§42) and that prison authorities 
have to safeguard the health of all prisoners (§39) (Council of Europe, 2006). In addition, a 
proposal for a Council recommendation is being developed to introduce harm reduction measures 
(including voluntary counselling and testing for infectious diseases) in prisons in the EU, following 
action 21 in the EU drugs action plan (2009–12), which states ‘To develop and implement 
prevention, treatment, harm reduction and rehabilitation services for people in prison, equivalent 
to services available outside prison. Particular emphasis to be placed on follow-up care after 
release from prison.’
The present guidelines recommend a provider-initiated approach for IDUs in most settings, 
provided that the client is actually able to decline some or all the tests and that this does not 
result in any negative consequences for them. It is important to note that in settings where 
these conditions are unlikely to be met, or where it is not possible to ensure a truly independent 
monitoring of those conditions, provider initiated testing and counselling should not be 
implemented other than for patients with clinical signs and symptoms. Testing should then 
generally be limited to making available voluntary counselling and testing only at the explicit 
request of the client.
Healthcare provider training
Training and ongoing supervision and monitoring of healthcare providers carrying out 
routine medical examination, testing and counselling with IDUs is required for the successful 
implementation of the service.
Training programmes for personnel should be developed and implemented well in advance of 
setting up the service in various health facility settings. Training should be based on protocols that, 
besides medical issues, should address specifically the following key areas:
ensuring an ethical process, including obtaining informed consent and the possibility of  ▯
declining testing for HIV or other infections;
protecting the confidentiality and privacy of clients; ▯
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avoiding stigmatisation and treating all clients with respect and without discrimination on the  ▯
basis of their HIV status or risk behaviour;
opposing negative attitudes among healthcare providers towards IDUs. ▯
It is of particular importance that such training is provided to healthcare providers in prisons and 
other closed settings such as compulsory residential rehabilitation where IDUs may be more likely 
to experience coercion.
Adaptation of the guidelines
Success in the implementation of routine medical examination, testing and counselling in IDUs will 
depend on an assessment of a particular country with regard to the epidemiological situation, the 
healthcare system, and available financial and human resources. In addition, a country’s social, 
policy and legal frameworks for protection against discrimination of people living with HIV or 
other chronic drug-related infections must be taken into consideration.
Chapter 4: Implementation
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Abbreviations
ALAT    alanine aminotransferase (liver function test)
ART    antiretroviral therapy
ASAT    aspartate aminotransferase (liver function test)
BCG    Bacille Calmette Guérin (vaccine)
CRP    C-reactive protein
DNA    deoxyribonucleic acid
EIA    enzyme-linked immunoassay
ELISA    enzyme-linked immunoassay
EMCDDA European Monitoring Centre for Drugs and Addiction
ESR  erythrocyte sedimentation rate
FTA  fluorescent treponemal antibody absorption test (syphilis test)
HBV  hepatitis B virus
HCV  hepatitis C virus
HIV  human immunodeficiency virus
HTLV  human T-cell lymphotropic virus
HPV  human papillomavirus
IDU  injecting drug user
IGRA  IFN-gamma release assays (tuberculosis test)
MRSA  methicillin resistant Staphylococcus aureus
MSM  men who have sex with men
NAAT  nucleic acid amplification tests
PCR  polymerase chain reaction
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POCT  point of care testing (using rapid test)
RPR  rapid plasma reagin test (syphilis test)
STI  sexually transmitted infections
TB  tuberculosis
TST  tuberculin skin test
TPHA  Treponema pallidum haemagglutination test (syphilis test)
UNODC The United Nations Office on Drugs and Crime
UNAIDS Joint United Nations Programme on HIV and AIDS
VDRL  Venereal disease research laboratory test (syphilis test)
WHO  World Health Organization
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Glossary
Client-initiated examination, testing and counselling The individual actively seeks 
examination, testing and counselling at a facility that offers these services. The procedure usually 
involves a risk assessment by the individual and management by the counsellor, addressing issues 
such as the desirability and implications of testing for various agents. It may be conducted in a 
wide variety of settings including health facilities, stand-alone facilities, via mobile services, in 
community-based settings and even in people’s homes.
Provider-initiated examination, testing and counselling A healthcare provider recommends 
examination, testing and counselling to people attending facilities as a standard component of 
medical care. The person involved may have attended the facility for reasons such as specific 
medical or other health problems, rehabilitation, use of harm reduction measures or social and 
economic needs. The objective of provider-initiated testing is to identify specific infections in 
people with signs or symptoms that could be attributable to HIV and other infections. In addition, 
unrecognised or unsuspected infections can be identified in individuals with no specific signs or 
symptoms. Both client-initiated and provider-initiated examination, testing and counselling are 
voluntary and the ‘three Cs’ — informed consent, counselling and confidentiality — must be strictly 
observed.
Informed consent This involves a process of communication between client and provider 
that results in the patient agreeing to voluntarily undergo testing or any other specific medical 
intervention. Elements of informed consent typically include providing oral or written information 
to the client about the proposed procedure that stresses the voluntary aspect of taking the test or 
intervention.
Opt-in approach Clients are offered testing, and if they agree, they must provide explicit consent 
once they have received pre-test information.
Opt-out approach Clients are informed that testing will be performed as a part of their care, 
unless they explicitly decline. Informed consent is assumed unless the patient declines to be tested. 
No tests are carried out against a person’s wishes or without their knowledge.
Screening Screening involves carrying out a laboratory test for all the people in a defined 
population.
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Drug-related infections Any infections disproportionally found in (injecting) drug users as 
compared to the general population.
Client-centred prevention counselling Tailoring a discussion of risk reduction to the patient’s 
individual situation.
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